• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.

作者信息

Berkowitz Callie, Wilson Samuel, Key Nigel S, Ellsworth Patrick

机构信息

Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA.

Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA.

出版信息

J Thromb Haemost. 2024 Sep;22(9):2674-2675. doi: 10.1016/j.jtha.2024.04.027.

DOI:10.1016/j.jtha.2024.04.027
PMID:39174232
Abstract
摘要

相似文献

1
Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.利用2018 - 2022年美国食品药品监督管理局不良事件报告系统数据比较接受凝血因子VIII产品和艾美赛珠单抗治疗患者的血栓形成不良事件：来自伯克维茨等人的评论
J Thromb Haemost. 2024 Sep;22(9):2674-2675. doi: 10.1016/j.jtha.2024.04.027.
2
Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data.使用2018 - 2022年美国食品药品监督管理局不良事件报告系统数据，比较接受凝血因子VIII产品和依美珠单抗治疗的患者的血栓形成不良事件。
J Thromb Haemost. 2024 Jun;22(6):1640-1648. doi: 10.1016/j.jtha.2024.02.009. Epub 2024 Feb 22.
3
Safety first: Tracking adverse events associated with new therapies for people with hemophilia.安全第一：追踪与血友病患者新疗法相关的不良事件。
J Thromb Haemost. 2021 Jan;19 Suppl 1:3-5. doi: 10.1111/jth.15188.
4
Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab.接受艾美赛珠单抗治疗的血友病A患者中用于检测VIII因子抑制剂的显色贝塞斯达试验的验证
Int J Lab Hematol. 2021 Apr;43(2):e84-e86. doi: 10.1111/ijlh.13384. Epub 2020 Nov 10.
5
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.rFVIIa 与emicizumab 给药用于伴抑制物的先天性血友病 A 的安全性分析：来自 HAVEN 临床项目的经验。
J Thromb Haemost. 2019 Sep;17(9):1470-1477. doi: 10.1111/jth.14491. Epub 2019 Jun 17.
6
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.艾美赛珠单抗预防无抑制剂的血友病 A 患者出血。
N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550.
7
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.依库珠单抗预防伴抑制物的血友病 A。
N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.
8
Emicizumab-kxwh: First Global Approval.依美珠单抗-kxwh：全球首次获批。
Drugs. 2018 Feb;78(2):269-274. doi: 10.1007/s40265-018-0861-2.
9
Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A.艾美赛珠单抗预防治疗 A 型血友病患者的安全性评估。
Expert Opin Drug Saf. 2021 Apr;20(4):387-396. doi: 10.1080/14740338.2021.1893303. Epub 2021 Feb 27.
10
Measurement of antifactor VIII antibody titre in the presence of emicizumab; Use of chromogenic Bethesda assays.在emicizumab存在的情况下抗因子VIII抗体滴度的测定；发色贝塞斯达试验的应用。
Int J Lab Hematol. 2021 Aug;43(4):O204-O206. doi: 10.1111/ijlh.13518. Epub 2021 Mar 25.